Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma : Journal of Immunotherapy

Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
Basic Studies

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

Müller, Nadja*; Michen, Susanne*; Tietze, Stefanie*; Töpfer, Katrin*; Schulte, Alexander; Lamszus, Katrin; Schmitz, Marc; Schackert, Gabriele*,§; Pastan, Ira; Temme, Achim*,§

Author Information
doi: 10.1097/CJI.0000000000000082
  • Buy
  • SDC

Abstract

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.